About us
ABOUT US
Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases.
READ MORE
Company Overview
Cancer Immunotherapy
Infectious Diseases
Management
Board of Directors
Diversity in the Board

Corporate Governance
Board Committees
Remuneration Policy
Articles of Association

Corporate Social Responsibility
Privacy
Applicants
Shareholders
Visitors
Pipeline
PIPELINE
Our pipeline comprises multiple product candidates which are subject to more than 20 ongoing clinical studies in infectious diseases and cancer. Many of our programs are supported by external funding through either private or governmental partnerships.
Read more
IMVAMUNE
MVA-BN RSV
MVA-BN Filo
MVA-BN HPV
MVA-BN HIV
MVA-BN HBV

CV301
BN-Brachyury
PROSTVAC

Technology
MVA-BN
Clinical Trials
Expanded Access Policy
Publications
IMVAMUNE
MVA-BN Filo
CV301
BN-Brachyury
PROSTVAC
INVESTORS
INVESTORS
Bavarian Nordic is committed to providing our shareholders and the media with reliable and transparent information about our business, development programs and results in an open and timely manner
Read more
News
Subscribe
Events & Presentations
Downloads
Financial Reports
CSR Reports
Image Archive

Share Information
Stock Chart
Analysts
Ownership
ADR Program

Annual General Meeting
Shareholder Portal
FAQ
Contact
IR Policy
Careers
CAREERS
Bavarian Nordic offers a challenging international working environment in which
job satisfaction and personal growth have a high priority.
READ MORE
Working With Us
Our Values
Our Employee Philosophy
Our Code of Ethics

Our Employees
Kvistgaard - Denmark
Martinsried - Germany

The Recruitment Process
Privacy Notice for Applicants
Job Openings
For Students

News

Click here for news in Danish.

September 19, 2018 | Press Releases

Bavarian Nordic Delivers Smallpox Vaccine to England in Response to Current Monkeypox Cases

September 18, 2018 | Company Announcements

Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Atezolizumab in Bladder Cancer

August 21, 2018 | Press Releases

Importance of Smallpox Vaccination Highlighted in Biopreparedness Exercise

August 16, 2018 | Company Announcements

Bavarian Nordic Announces First Half 2018 Results

August 09, 2018 | Company Announcements

Bavarian Nordic Granted EUR 30 Million Loan from The European Investment Bank

August 08, 2018 | Company Announcements

Bavarian Nordic Announces Positive Data from Phase 2 Extension Study of its Universal RSV Vaccine

July 11, 2018 | Company Announcements

Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer

June 07, 2018 | Company Announcements

Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

May 31, 2018 | Company Announcements

Bavarian Nordic Announces Appointment of Henrik Juuel as Chief Financial Officer

May 24, 2018 | Company Announcements

Bavarian Nordic Announces Interim Results for the First Three Months of 2018

May 16, 2018 | Press Releases

Bavarian Nordic Announces Acceptance of Abstracts and Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 02, 2018 | Company Announcements

Bavarian Nordic Receives FDA Orphan Drug Designation for BN-Brachyury for the Treatment of Chordoma

April 17, 2018 | Company Announcements

Bavarian Nordic A/S – Report on the Results of the Annual General Meeting, held April 17, 2018

March 26, 2018 | Company Announcements

Bavarian Nordic A/S – Notice Convening Ordinary General Meeting

March 16, 2018 | Company Announcements

Bavarian Nordic Announces Partnership with U.S. Department of Defense to Combat Equine Encephalitis Virus

March 12, 2018 | Company Announcements

Bavarian Nordic Awards Restricted Stock Units to Executive Management

March 12, 2018 | Company Announcements

Bavarian Nordic Announces Annual Report 2017

March 08, 2018 | Company Announcements

Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer

March 06, 2018 | Company Announcements

Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine

February 26, 2018 | Company Announcements

Bavarian Nordic Announces Collaboration to Evaluate CV301 in Combination with durvalumab in Colorectal and Pancreatic Cancers

February 06, 2018 | Company Announcements

Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of IMVAMUNE® Smallpox Vaccine

January 31, 2018 | Company Announcements

Bavarian Nordic Announces the Planned Departure of Chief Financial Officer, Ole Larsen

January 19, 2018 | Company Announcements

Bavarian Nordic Announces Initiation of Clinical Trial with Novel Cancer Immunotherapy Targeting Brachyury in Cancer Metastasis